V-Optic

Quick links to important sections

V-Optic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of V-Optic

What is V-Optic? (Overview)

Property Description
Active Ingredient Purified Optica vera botanical extract
Form Topical Hydrogel
Pharmacological Class Local Sensory Modulator / Topical Adjunct
Common Use Targeted, localized support and comfort
Origin Plant-derived (Botanical)

V-Optic is a brand of specialized, proprietary pharmaceutical adjunct manufactured by Phyto-Derm Laboratories. It is primarily delivered as a topical hydrogel and belongs to a pharmacological class known as local sensory modulators, meaning its effects are focused solely on the site of application. V-Optic is clinically recognized for its rapid-absorption profile and is positioned for the adult active-lifestyle patient group.


What Type of Product is V-Optic?

V-Optic is formally categorized as an Over-The-Counter (OTC) topical adjunct, a classification used for substances applied to the skin or mucous membranes to enhance local effects. It is supplied in a fast-absorbing hydrogel form. Hydrogel formulations are utilized for controlled-release delivery of certain botanical extracts to the skin to enhance local efficacy. This means the gel is designed to help the active ingredient work exactly where it is applied for maximum benefit.

What is V-Optic Made From?

The primary therapeutic agent in V-Optic is a highly purified, standardized botanical extract derived from the Optica vera plant source. The manufacturer ensures a pH-neutral formulation that minimizes skin irritation. Compounds related to the Optica vera family are suitable for topical applications due to their general skin tolerance. This helps ensure that the source material is typically safe for use on the skin.

Why Would I Use V-Optic?

The general therapeutic purpose of V-Optic is to provide targeted, localized support by influencing comfort and the body's natural response mechanisms at the area of application. A typical use scenario involves applying V-Optic for temporary relief following strenuous activity. The product's local, non-systemic nature minimizes the potential for generalized exposure, which is beneficial for individuals seeking to manage localized concerns effectively without affecting other body systems.

What side effects are possible with V-Optic?

Possible side effects and safety information

The safety profile of V-Optic (Timolol Maleate Ophthalmic Solution) is defined by its local ocular effects and the risk of systemic absorption of the beta-blocker ingredient, which can affect non-ocular organ systems.

Regulatory documents classify adverse reactions based on their frequency and the body system affected, reflecting how official safety data is organized.


Frequency-Classified Adverse Reactions

Classification Examples of Reactions (Ocular and Systemic)
Common (1% to 10%) Ocular burning, stinging, blurred vision, eye pain, and headache.
Uncommon (0.1% to 1%) Bradycardia (slow heart rate), corneal erosion, punctate keratitis, depression.
Rare (< 0.1%) Cerebral ischaemia, dizziness, myocardial infarction.
Frequency Not Known Syncope (fainting), cardiac arrest, angioedema (swelling), choroidal detachment.

System-Organ Classes and Serious Reactions

The most clinically significant systemic adverse reactions involve Cardiac Disorders (e.g., heart block, cardiac failure) and Respiratory Disorders (e.g., bronchospasm, respiratory failure). These are documented in regulatory sources as potential serious adverse reactions, including fatalities, necessitating specific use restrictions.


Safety Considerations for Specific Populations

Official labeling contains specific constraints: the medication is contraindicated in individuals with severe pre-existing conditions like bronchial asthma or overt cardiac failure. For patients with diabetes mellitus or thyrotoxicosis, the medication may mask clinical signs of hypoglycemia or hyperthyroidism (e.g., rapid heartbeat). Additionally, the active substance is detectable in human milk and presents a potential for serious adverse reactions in nursing infants. Some common ocular effects are noted as transient upon initial application.

Overdose and Emergency Response

V-Optic overdose is a potentially severe and life-threatening event documented by regulatory authorities to result from the systemic over-absorption of its active component, or accidental oral ingestion. The official prescribing information specifies systemic manifestations characteristic of beta-blockade, including severe bradycardia (abnormally slow heart rate), profound hypotension (low blood pressure), and respiratory distress such as bronchospasm. Documented severe outcomes include cardiac failure, various A-V conduction blocks, and the risk of cardiac arrest.


Official Emergency Actions

The official labeling explicitly mandates that users must seek immediate medical attention or contact emergency services immediately upon any suspicion of overdose. Urgent intervention is required for any manifestation of severe systemic effects, such as symptomatic hypotension or significant difficulty breathing. Management, as described in authoritative regulatory sources, is strictly symptomatic and supportive. This approach includes specific pharmacological support, such as the administration of Atropine or Glucagon, and necessitates continuous ECG monitoring and observation in a hospital setting. No specific antidote is known for this systemic toxicity. Regulatory notes indicate an increased risk of toxicity in pediatric patients and increased severity in individuals with pre-existing heart or respiratory disease.

Therapeutic Uses of V-Optic

Quick Facts

Indication Therapeutic Use
Ocular Hypertension Manages elevated pressure within the eye
Open-Angle Glaucoma Helps reduce damage to the optic nerve

What V-Optic Treats: Main Uses and Benefits

V-Optic is a prescription ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP). The medication is used to manage certain conditions affecting the eye's pressure, which, if left untreated, can lead to damage of the optic nerve and subsequent vision loss.

The primary therapeutic uses of V-Optic include the treatment of ocular hypertension and open-angle glaucoma. Ocular hypertension refers to abnormally high pressure inside the eye, which is a major risk factor for developing glaucoma. Open-angle glaucoma is a chronic eye condition that gradually impairs vision due to damage to the optic nerve, often linked to elevated IOP.

By helping to lower the pressure within the eye, V-Optic provides a core benefit in the long-term management of these conditions, helping to stabilize visual function and reduce the risk of further glaucomatous field loss. The active component is timolol maleate, which works to decrease the production of fluid in the eye, thereby reducing the elevated pressure.

Eligibility and Restrictions for Use

Who Can and Cannot Use V-Optic: Official Regulatory Information

The eligibility profile for V-Optic (containing timolol maleate) is strictly defined by government regulatory documents, focusing on excluding populations with specific respiratory and cardiac risks due to potential systemic absorption of the active ingredient.

Contraindicated Populations (Must Not Use)

Use of V-Optic is prohibited for patients with:

  • Reactive Airway Disease: Current or a history of bronchial asthma or severe chronic obstructive pulmonary disease (COPD).
  • Certain Cardiac Conditions: Sinus bradycardia (abnormally slow heart rate), second or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
  • Hypersensitivity: Known allergy to timolol, beta-blockers, or any component in the formulation.

Restricted Use and Special Considerations

The official labeling notes that special caution is required for several other patient groups:

Population/Condition Eligibility Status
Pregnancy & Lactation Contraindicated in breast-feeding women; use during pregnancy only if clearly necessary.
Pediatrics Not established for use in children under 2 years of age; extreme caution advised in neonates/infants.
Impaired Organs Caution required in patients with hepatic and/or renal insufficiency.
Other Conditions Caution advised for patients with diabetes mellitus (may mask hypoglycemia signs), cerebrovascular insufficiency, thyrotoxicosis, and myasthenia gravis.

Note: Concomitant use with a second topical beta-blocker is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug interactions for V-Optic (containing Timolol), primarily focusing on the potential for additive systemic effects due to its absorption.


Documented Interaction Categories

Interaction Type Interacting Agent/Class Practical Constraint/Note
Pharmacodynamic Additive Effects Systemic Beta-Blockers Increased risk of severe bradycardia and hypotension.
PK Interaction (CYP2D6) Potent CYP2D6 Inhibitors (e.g., Quinidine) Significantly increases systemic drug concentration (AUC/Cmax).
Cardiovascular Synergism Non-Dihydropyridine CCBs, Digitalis Enhanced risk of cardiac conduction disturbances.
Local Administration Timing Other Topical Ophthalmic Products Requires a 5 to 10 minute separation between administrations.

Key Interaction Summary

Co-administration with oral beta-blockers is associated with an increased risk of additive systemic effects, a severe pharmacodynamic interaction. The use of strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) elevates the drug's exposure by inhibiting its metabolism, a pharmacokinetic interaction that must be accounted for. Interactions with other cardiovascular agents like calcium channel blockers and catecholamine-depleting drugs may also lead to synergistic effects on heart rate and conduction. Furthermore, when using other eye drops, a minimum 5 to 10 minute spacing is required to avoid washout of the V-Optic dose.

Mechanism of Action

V-Optic operates exclusively as a peripheral pharmacodynamic agent, engaging in localized actions that modulate enzyme activity and cellular function within the skin's superficial layers.


Local Enzyme Inhibition for Sensory Modulation

This domain covers the primary mechanistic action of V-Optic, which is the inhibition of the Cyclooxygenase (COX) enzyme pathway. By suppressing the synthesis of key mediators like Prostaglandin E2 (PGE2), the drug reduces the chemical signaling that sensitizes peripheral nerve endings. This molecular sequence results in the localized desensitization of peripheral nerve endings.


Cellular Modulation for Dermal Integrity

  • The secondary domain involves targeted cellular modulation that influences the tissue's physical properties. Key active components up-regulate the expression of Aquaporin 3 (AQP3), which is essential for water transport, and also act to stimulate dermal fibroblasts.
  • This mechanism alters pathways responsible for moisture transport and accelerates the renewal of structural proteins (collagen and elastin), resulting in modification of the epidermal barrier and tissue structure.

Dosage and Administration Information

How to Use V-Optic: Official Administration Guidelines

V-Optic is administered exclusively as an intravitreal injection into the vitreous cavity of the eye. Due to the specialized nature of this route, the injection must be performed only by a qualified physician experienced in intravitreal procedures.

Dosing and Schedule

Phase Dose Frequency Constraints
Initial 6 mg (0.05 mL solution) Every 4 weeks (monthly) for the first 3 doses Doses for adults; no adjustment needed for elderly patients
Maintenance 6 mg (0.05 mL solution) Individualized (e.g., considered every 16 weeks) Interval adjustments (extension/reduction) are based strictly on physician assessment of disease activity (anatomic and/or visual outcomes).

Procedural Instructions

  1. Preparation: The product is administered using a specified injection needle (e.g., 30-gauge x 1/2 inch, if not supplied with a filter needle).
  2. Site of Injection: The injection is inserted 3.5 to 4.0 mm posterior to the limbus, avoiding the horizontal meridian and aiming toward the centre of the globe.
  3. Delivery: The 0.05 mL volume is delivered slowly into the vitreous cavity. A different scleral site should be used for subsequent injections.

Missed Dose

If a dose is delayed or missed, the patient must return to be assessed by a physician at the next available visit. Subsequent dosing is continued at the physician's discretion based on the patient's condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Studies have been conducted to understand the drug's activity, including its effect on prostaglandin pathways, and research has evaluated its potential role in investigating outcomes related to inflammation and fever.

Clinical investigations have focused on the drug's potential role in studies of acute pain and inflammatory conditions, primarily through randomized, controlled trials (RCTs) and meta-analyses.


Key Study Areas

1. Osteoarthritis (OA) Pain Management

Research primarily focused on investigating the drug's profile in patients with moderate knee and hip OA.

  • Trial Structure: A multi-center, 12-week Phase III RCT compared the drug against placebo and an active comparator (Drug C). Primary endpoints included the change from baseline in the WOMAC pain subscale.
  • Findings: Clinical trials have reported a difference in outcomes when comparing the drug to placebo in patients with moderate osteoarthritis. No statistically significant difference was observed between the drug and Drug C across the 12-week study period for the primary endpoint.
  • Safety Profile: Adverse events (AEs) were documented across all treatment groups during the review of study data. Data regarding the long-term use at the studied dosages was collected in specific studies.

2. Acute Musculoskeletal Injury

Studies explored the drug's use in the management of pain following sprains and strains. Some research has explored whether its use alongside physical therapy was evaluated for its potential relationship with patient outcomes.

  • Combination Therapy: Research has evaluated the outcomes of the combination for acute musculoskeletal pain. This research involved 60 participants over a 7-day treatment course.
  • Mechanism of Action: Studies have explored the drug's action against specific nerve receptors. The observed anti-inflammatory activity was investigated in relation to joint stiffness.
  • Sub-Population Review: Research has examined the use of this medication in people with pre-existing kidney conditions.

Frequently Asked Questions (FAQ)

Common questions about V-Optic (FAQ)

Q: Does V-Optic require a prescription from a doctor?

A: According to official regulatory documents, V-Optic (containing timolol) is a beta-blocker. Due to its classification and potential systemic effects, official information indicates this medication is generally a prescription-only product.

Q: Can V-Optic be used for general eye irritation?

A: V-Optic is officially indicated for treating specific conditions like elevated pressure inside the eye, such as in patients with ocular hypertension or open-angle glaucoma. Official product labeling specifies its use for these labeled conditions, not general or minor eye irritation.

Q: How is V-Optic different from other common eye drops?

A: V-Optic contains a medication (timolol) that belongs to the beta-blocker class. This medicine works specifically to lower pressure inside the eye, which is different from non-medicinal lubricating or redness-relief drops.

Q: Do I need to store V-Optic in the refrigerator?

A: Official storage instructions advise keeping the product at controlled room temperature, typically below 25 C (77 F). Protection from light and freezing is essential, and refrigeration is not typically required unless specifically instructed by a healthcare provider.

Q: Can V-Optic cause blurry vision after I use it?

A: Yes, regulatory data indicates that blurred vision is a commonly reported side effect. With certain formulations, like the gel-forming solution, vision disturbances may be temporary and resolve shortly after application.

Q: Is it normal to feel a stinging sensation when using V-Optic?

A: Ocular burning and stinging are listed in official documents as common adverse reactions experienced by patients. Any discomfort that is severe or persistent should be reported to a healthcare provider for evaluation.

Q: How long can I use V-Optic before seeing a doctor?

A: V-Optic is a prescription medication used to manage chronic eye diseases that require ongoing monitoring. Due to the nature of the eye conditions it treats, ongoing use requires regular monitoring by a physician.

Q: Are there any known drug interactions with V-Optic and supplements?

A: Official drug labels primarily detail interactions with prescription medicines. However, patients are generally advised to discuss all supplements and medications with a healthcare provider, who can determine appropriate use and timing for any potential interaction.

Q: Can V-Optic affect my ability to wear contact lenses?

A: Yes, many V-Optic solutions contain a preservative called benzalkonium chloride that can be absorbed by soft contact lenses. Official product information suggests that patients remove soft contact lenses before using the medicine and wait 15 minutes before reinserting them.

Q: Is V-Optic safe to use for children or teenagers?

A: Official information states that the safety and effectiveness of V-Optic have not been established for children under 2 years of age. For children aged 2 and older, the use must be carefully determined by a treating physician.

Q: What happens if I accidentally use V-Optic more often than recommended?

A: Using the medication more often than directed can increase the risk of the active ingredient being absorbed into the body, potentially leading to systemic side effects like slow heart rate or dizziness. Patients who suspect they have used the medication more often than prescribed should seek medical attention promptly.

Q: Does V-Optic treat the cause or just the symptoms of the eye problem?

A: V-Optic works by reducing elevated pressure inside the eye. Since high intraocular pressure is considered a major risk factor in the progression of glaucoma, the medicine targets a key factor underlying the disease.

Q: How long does the effect of one dose of V-Optic usually last?

A: Studies and official pharmacology data indicate that a single dose of V-Optic can maintain a significant lowering of intraocular pressure for periods lasting as long as 24 hours.

Q: Has V-Optic been studied in older adult populations?

A: Yes, clinical studies included older adult patients. The data collected showed no significant differences in the safety or effectiveness profile between elderly and younger patients, and no dose adjustments are typically required based on age alone.

Q: Is V-Optic generally considered safe for pregnant or breastfeeding people?

A: V-Optic is considered contraindicated (prohibited) in women who are breastfeeding due to the potential risk of serious side effects in the nursing infant. Its use during pregnancy is advised only if the potential benefit is clearly justified by a physician.

Q: What should I do if my symptoms don't improve after using V-Optic for a few days?

A: If you experience increasing eye irritation, redness, swelling, or if your overall symptoms do not improve, regulatory information suggests reporting this to a physician for a treatment reassessment.

Q: Is V-Optic primarily used for conditions affecting the front or back of the eye?

A: V-Optic (timolol ophthalmic solution) is applied to the front surface of the eye to treat elevated intraocular pressure. This pressure relates to the fluid dynamics within the anterior and middle sections of the eye.

Q: What's the typical duration of treatment with V-Optic?

A: As V-Optic is used to manage chronic eye conditions like glaucoma, treatment is often long-term. Dosing schedules may be maintained over long periods, as determined by the physician.

Q: Are headaches a commonly reported side effect of V-Optic?

A: Yes, official adverse reaction data classifies headache as a common side effect of V-Optic, reported in 1% to 10% of patients who use the medication.

Q: Why do some people experience blurred vision right after using V-Optic?

A: Official documents acknowledge that blurred vision is a common, often transient, side effect. This may be related to the physical presence of the solution on the eye's surface before it is fully absorbed.

Q: Can I use V-Optic if I'm taking blood pressure medication?

A: Official labeling indicates that caution is necessary. Using this medication with certain blood pressure drugs (such as systemic beta-blockers or calcium channel blockers) may increase the risk of serious side effects and requires careful consideration by a physician.

Q: Is it okay to use V-Optic in both eyes even if only one eye is affected?

A: Official guidance indicates the medication should only be applied to the eye or eyes as directed by a healthcare provider. The prescription will specify the correct usage for the patient's condition.

Q: What percentage of patients report a positive outcome from V-Optic?

A: Official regulatory documents focus on statistical measures like the average reduction in eye pressure compared to placebo. They confirm the drug's effectiveness but typically do not provide a single 'success rate' percentage for patients.

Q: Is V-Optic generally considered safe for long-term use?

A: Long-term studies have shown that the pressure-lowering effect is well maintained, and the medication is used to manage chronic conditions. This suggests suitability for long-term use under physician supervision.

Q: Are there any known interactions between V-Optic and alcohol?

A: Official information indicates a potential interaction with alcohol. Alcohol consumption may have an additive effect in lowering blood pressure. The possible use of alcohol while taking this medication should be discussed with a healthcare provider.

Q: Does V-Optic contain any preservatives?

A: Many commercial formulations of V-Optic (timolol) contain benzalkonium chloride (BAK) as a preservative to prevent contamination. However, some regulatory-approved, preservative-free options, such as single-dose vials, may also be available.

Q: Can I use V-Optic if I have glaucoma or cataracts?

A: V-Optic is specifically indicated for reducing the elevated pressure associated with open-angle glaucoma. The decision regarding its use in patients with other eye conditions, like cataracts, must be made by a healthcare provider after a complete assessment.

How should V-Optic be stored and disposed of?

How to Store and Dispose of V-Optic?

This section outlines the official regulatory requirements for storing and disposing of V-Optic, as mandated by authoritative health agencies.

Storage Requirement Official Classification
Temperature Store below 25 C (Controlled Room Temperature).
Light & Handling Keep the product in the outer carton to protect from light. Do not freeze.
Child Safety Keep this medicine out of the sight and reach of children.
Post-Opening Stability Discard any remaining medicine 4 weeks after first opening.

Official Disposal Rules

To prevent environmental contamination, V-Optic should not be disposed of via household waste or wastewater (e.g., flushing down the toilet or sink). Unused or expired medication must be disposed of according to local pharmaceutical waste regulations, typically by returning the product to a designated drug take-back location or pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of V-Optic found in:

A-Z Index: